281 related articles for article (PubMed ID: 24344137)
1. The hypertrophic cardiomyopathy myosin mutation R453C alters ATP binding and hydrolysis of human cardiac β-myosin.
Bloemink M; Deacon J; Langer S; Vera C; Combs A; Leinwand L; Geeves MA
J Biol Chem; 2014 Feb; 289(8):5158-67. PubMed ID: 24344137
[TBL] [Abstract][Full Text] [Related]
2. Dilated cardiomyopathy myosin mutants have reduced force-generating capacity.
Ujfalusi Z; Vera CD; Mijailovich SM; Svicevic M; Yu EC; Kawana M; Ruppel KM; Spudich JA; Geeves MA; Leinwand LA
J Biol Chem; 2018 Jun; 293(23):9017-9029. PubMed ID: 29666183
[TBL] [Abstract][Full Text] [Related]
3. Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human β-cardiac myosin motor function.
Sommese RF; Sung J; Nag S; Sutton S; Deacon JC; Choe E; Leinwand LA; Ruppel K; Spudich JA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12607-12. PubMed ID: 23798412
[TBL] [Abstract][Full Text] [Related]
4. Biological, biochemical, and kinetic effects of mutations of the cardiomyopathy loop of Dictyostelium myosin II: importance of ALA400.
Liu X; Shu S; Kovács M; Korn ED
J Biol Chem; 2005 Jul; 280(29):26974-83. PubMed ID: 15897189
[TBL] [Abstract][Full Text] [Related]
5. Functional consequences of mutations in the smooth muscle myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy.
Yamashita H; Tyska MJ; Warshaw DM; Lowey S; Trybus KM
J Biol Chem; 2000 Sep; 275(36):28045-52. PubMed ID: 10882745
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.
Roopnarine O; Leinwand LA
Biophys J; 1998 Dec; 75(6):3023-30. PubMed ID: 9826622
[TBL] [Abstract][Full Text] [Related]
7. The Local Environment of Loop Switch 1 Modulates the Rate of ATP-Induced Dissociation of Human Cardiac Actomyosin.
Gargey A; Nesmelov YE
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163146
[TBL] [Abstract][Full Text] [Related]
8. A Failure to Communicate: MYOSIN RESIDUES INVOLVED IN HYPERTROPHIC CARDIOMYOPATHY AFFECT INTER-DOMAIN INTERACTION.
Kronert WA; Melkani GC; Melkani A; Bernstein SI
J Biol Chem; 2015 Dec; 290(49):29270-80. PubMed ID: 26446785
[TBL] [Abstract][Full Text] [Related]
9. Human myosin III is a motor having an extremely high affinity for actin.
Kambara T; Komaba S; Ikebe M
J Biol Chem; 2006 Dec; 281(49):37291-301. PubMed ID: 17012748
[TBL] [Abstract][Full Text] [Related]
10. Differential cross-bridge kinetics of FHC myosin mutations R403Q and R453C in heterozygous mouse myocardium.
Palmer BM; Fishbaugher DE; Schmitt JP; Wang Y; Alpert NR; Seidman CE; Seidman JG; VanBuren P; Maughan DW
Am J Physiol Heart Circ Physiol; 2004 Jul; 287(1):H91-9. PubMed ID: 15001446
[TBL] [Abstract][Full Text] [Related]
11. Converter domain mutations in myosin alter structural kinetics and motor function.
Gunther LK; Rohde JA; Tang W; Walton SD; Unrath WC; Trivedi DV; Muretta JM; Thomas DD; Yengo CM
J Biol Chem; 2019 Feb; 294(5):1554-1567. PubMed ID: 30518549
[TBL] [Abstract][Full Text] [Related]
12. Effect of phosphorylation in the motor domain of human myosin IIIA on its ATP hydrolysis cycle.
Komaba S; Watanabe S; Umeki N; Sato O; Ikebe M
Biochemistry; 2010 May; 49(17):3695-702. PubMed ID: 20192276
[TBL] [Abstract][Full Text] [Related]
13. Kinetic characterization of myosin head fragments with long-lived myosin.ATP states.
Friedman AL; Geeves MA; Manstein DJ; Spudich JA
Biochemistry; 1998 Jul; 37(27):9679-87. PubMed ID: 9657680
[TBL] [Abstract][Full Text] [Related]
14. Modeling the Actin.myosin ATPase Cross-Bridge Cycle for Skeletal and Cardiac Muscle Myosin Isoforms.
Mijailovich SM; Nedic D; Svicevic M; Stojanovic B; Walklate J; Ujfalusi Z; Geeves MA
Biophys J; 2017 Mar; 112(5):984-996. PubMed ID: 28297657
[TBL] [Abstract][Full Text] [Related]
15. Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance.
Seebohm B; Matinmehr F; Köhler J; Francino A; Navarro-Lopéz F; Perrot A; Ozcelik C; McKenna WJ; Brenner B; Kraft T
Biophys J; 2009 Aug; 97(3):806-24. PubMed ID: 19651039
[TBL] [Abstract][Full Text] [Related]
16. Familial hypertrophic cardiomyopathy associated with a novel missense mutation affecting the ATP-binding region of the cardiac beta-myosin heavy chain.
Bundgaard H; Havndrup O; Andersen PS; Larsen LA; Brandt NJ; Vuust J; Kjeldsen K; Christiansen M
J Mol Cell Cardiol; 1999 Apr; 31(4):745-50. PubMed ID: 10329202
[TBL] [Abstract][Full Text] [Related]
17. Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain.
Huang W; Liang J; Yuan CC; Kazmierczak K; Zhou Z; Morales A; McBride KL; Fitzgerald-Butt SM; Hershberger RE; Szczesna-Cordary D
FEBS J; 2015 Jun; 282(12):2379-93. PubMed ID: 25825243
[TBL] [Abstract][Full Text] [Related]
18. A Cardiomyopathy Mutation in the Myosin Essential Light Chain Alters Actomyosin Structure.
Guhathakurta P; Prochniewicz E; Roopnarine O; Rohde JA; Thomas DD
Biophys J; 2017 Jul; 113(1):91-100. PubMed ID: 28700929
[TBL] [Abstract][Full Text] [Related]
19. Myosin VI deafness mutation prevents the initiation of processive runs on actin.
Pylypenko O; Song L; Shima A; Yang Z; Houdusse AM; Sweeney HL
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1201-9. PubMed ID: 25751888
[TBL] [Abstract][Full Text] [Related]
20. Loop 1 of transducer region in mammalian class I myosin, Myo1b, modulates actin affinity, ATPase activity, and nucleotide access.
Clark R; Ansari MA; Dash S; Geeves MA; Coluccio LM
J Biol Chem; 2005 Sep; 280(35):30935-42. PubMed ID: 15980431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
